Moomoo AI 已提取核心信息
On February 28, 2024, 180 Life Sciences Corp. announced the appointment of Blair Jordan to its Board of Directors. Jordan, deemed independent according to Nasdaq Capital Market rules, will serve as a Class II director until the 2024 Annual Meeting of Stockholders. Concurrently, the Board set its membership at four and continues to seek qualified independent directors. Jordan brings extensive experience, including his current role as CEO of HighMont Advisors Inc. and senior advisor at Evans & Evans, Inc. His previous positions include CFO and interim CEO at Ascent Industries Corp., and he has served on multiple boards across various sectors. Jordan's appointment includes membership on several Board committees and he will receive an annual retainer fee, with half of his compensation deferred until the company raises $1 million. The company will enter into an indemnification agreement with Jordan, similar to those with other directors.
On February 28, 2024, 180 Life Sciences Corp. announced the appointment of Blair Jordan to its Board of Directors. Jordan, deemed independent according to Nasdaq Capital Market rules, will serve as a Class II director until the 2024 Annual Meeting of Stockholders. Concurrently, the Board set its membership at four and continues to seek qualified independent directors. Jordan brings extensive experience, including his current role as CEO of HighMont Advisors Inc. and senior advisor at Evans & Evans, Inc. His previous positions include CFO and interim CEO at Ascent Industries Corp., and he has served on multiple boards across various sectors. Jordan's appointment includes membership on several Board committees and he will receive an annual retainer fee, with half of his compensation deferred until the company raises $1 million. The company will enter into an indemnification agreement with Jordan, similar to those with other directors.
2024 年 2 月 28 日，180 生命科学公司宣布任命布莱尔·乔丹为其董事会成员。根据纳斯达克资本市场规则，乔丹被视为独立董事，将在2024年年度股东大会之前担任二类董事。同时，董事会将其成员人数定为四人，并继续寻找合格的独立董事。乔丹拥有丰富的经验，包括他目前担任HighMont Advisors Inc.首席执行官和埃文斯公司的高级顾问。他之前的职位包括Ascent Industries Corp的首席财务官和临时首席执行官，并曾在多个行业的董事会任职。乔丹的任命包括多个董事会委员会的成员，他将获得年度预付费，一半的薪酬将推迟到公司筹集100万美元之后。该公司将与约旦签订赔偿协议，类似于与其他董事的补偿协议。
2024 年 2 月 28 日，180 生命科学公司宣布任命布莱尔·乔丹为其董事会成员。根据纳斯达克资本市场规则，乔丹被视为独立董事，将在2024年年度股东大会之前担任二类董事。同时，董事会将其成员人数定为四人，并继续寻找合格的独立董事。乔丹拥有丰富的经验，包括他目前担任HighMont Advisors Inc.首席执行官和埃文斯公司的高级顾问。他之前的职位包括Ascent Industries Corp的首席财务官和临时首席执行官，并曾在多个行业的董事会任职。乔丹的任命包括多个董事会委员会的成员，他将获得年度预付费，一半的薪酬将推迟到公司筹集100万美元之后。该公司将与约旦签订赔偿协议，类似于与其他董事的补偿协议。
有用
没用